Items 31 ~ 32 of 2176, Page 4 of 272
Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
Phase 1 Data Presented Today at IAS 2019
Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment
Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Tr...
Medtronic Requests Approval of Non-Adjunctive Labeling from FDA
DUBLIN, July 23, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT),?the global leader in medical technology, services and solutions, today announced...
Merck Announces Fourth-Quarter 2019 Dividend
Medtronic Partners with Viz.ai to Accelerate Adoption of New Artificial Intelligence Software in U.S. Stroke Centers
Technology Has the Potential to Save Crucial Time and Increase Access to Lifesaving Stroke Treatments
Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect
New Connected Feeder Helps Pet Owners Monitor and Understand Eating Behavior of Pets
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
Abbott Reports Second-Quarter 2019 Results
ABBOTT PARK, Ill., July 17, 2019 /PRNewswire/ --?Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2019.